share_log

Earnings Call Summary | American Shared Hospital Services(AMS.US) Q4 2023 Earnings Conference

moomoo AI ·  Mar 28 14:44  · Conference Call

The following is a summary of the American Shared Hospital Services (AMS) Q4 2023 Earnings Call Transcript:

Financial Performance:

  • American Shared Hospital Services reported Q4 revenue of $5.7 million, a YoY increase of 13%.

  • Gross margin for the same period was $2.8 million or 49% of revenue, a rise of 24% YoY.

  • The EPS for the company stood at $0.06, in spite of additional costs and asset reserves.

  • For the entire year of 2023, the revenue increased by 8% reaching $21.3 million, and gross margin was $9.3 million, a rise of 11.5%.

  • The cash and equivalent at year end stood at $13.8 million, approximately equal to $2.19 per share.

Business Progress:

  • AMS ended the year with a robust sales pipeline, due to improvements in the sales team, expanding financial solutions and closer integration with strategic OEMs.

  • The company executed equipment upgrades in Ecuador, driving volume growth.

  • The company is planning to open an international center in Puebla, Mexico in Q2 2024 and expand business models to include development of their own majority-owned Proton Beam and radiation oncology centers in the US.

  • AMS acquired a majority interest in three radiation therapy cancer centers in Rhode Island, signaling its entry into direct patient services in the US.

  • The company expects further growth from international business due to additional treatment capacities in Ecuador, the new center in Puebla, and projected closing of the Rhode Island acquisition.

More details: American Shared Hospital Services IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment